We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drug companies’ returns on R&D investments have sunk to their lowest level since 2010 and analysts at Deloitte attribute the decline mostly to the soaring costs of clinical trials. Read More
The state’s supreme court affirmed that the sudden downturn in Akorn’s generic drug business — before the deal was final — justified Fresenius’ reversal. Read More
A month after a scathing congressional report hit Kaléo for hiking prices for its opioid antidote by 600 percent, the company announced it will release a lower-cost generic version of its auto-injector in 2019. Read More
Three former Genentech employees were indicted by a federal grand jury for allegedly stealing trade secrets from the San Francisco-based Roche subsidiary, which is pursuing litigation of its own against the ex-staffers. Read More
Allegedly, Xanthe Lam’s more than 30 years as a principal scientist at Genentech gave her access to valuable intellectual property and secure document repositories. Read More
Three former Genentech employees were indicted by a federal grand jury for allegedly stealing trade secrets from the San Francisco-based Roche subsidiary, which is pursuing litigation of its own against the ex-staffers. Read More
Spring Pharmaceuticals sued incarcerated ex-pharma CEO Martin Shkreli and his former biopharmaceutical company Retrophin for blocking generics of its kidney stone drug Thiola. Read More
An outside consultant hired by Insys found serious compliance issues with the speakers programs, such as an absence of safety content and no clear disclosure of Insys sponsorship. Read More
The Attorney General said the company distributed the copayment coupons to consumers throughout New York “without clearly and conspicuously disclosing” the terms and conditions. Read More